Expert review of pharmacoeconomics & outcomes research · 2025
Economic evaluation of an add-on module to reduce intrusive suicidal mental images in patients with depressive symptoms.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Bentum Jaël, Wijnen Ben, Bachrach Nathan, Creemers Daan, van Dijk Maarten K, Dingemanse Pieter, van Haaren Monique, Stikkelbroek Yvonne, Van Henricus L, Vrijsen Janna N, de Winter Remco F P, Sijbrandij Marit
Аннотация
BACKGROUND: Previous research demonstrated the effectiveness of an add-on module in reducing intrusive suicidal mental images in patients with elevated depression symptoms indicative of a depressive disorder. This study assessed the cost-effectiveness of combining this module with treatment as usual (TAU) versus TAU-alone.
RESEARCH DESIGN AND METHODS: A randomized controlled trial of 91 participants (46 add-on+TAU, 45 TAU). Cost-effectiveness was assessed over 12 months using quality-adjusted life years (QALYs) as the primary outcome. Healthcare, patient, and work-related costs were measured. Health-related quality of life was assessed using EQ-5D-5 L at baseline, and after 3, 6, 9, and 12 months.
RESULTS: The add-on+TAU group showed slightly higher QALYs (0.674) than TAU-group (0.630) after 12 months. From a societal perspective, the intervention yielded an incremental cost-effectiveness ratio of €137,285 per QALY gained (95% CI: -€7,338 to €15,656; QALY gain: 0.0274). Healthcare costs were higher in the add-on+TAU group, primarily due to increased outpatient mental care costs (including intervention costs of €524.02/participant). The intervention showed a 35% probability of cost-effectiveness at an €80,000 willingness-to-pay threshold.
CONCLUSIONS: Although the add-on module reduced suicidal mental images, its cost-effectiveness remains uncertain. Modest QALY improvements did not justify increased healthcare and societal costs. Larger-scale studies with extended follow-up are needed.
CLINICAL TRIAL REGISTRATION: The trial was prospectively registered in the Netherlands Trial Registry (No. NTR7563).
RESEARCH DESIGN AND METHODS: A randomized controlled trial of 91 participants (46 add-on+TAU, 45 TAU). Cost-effectiveness was assessed over 12 months using quality-adjusted life years (QALYs) as the primary outcome. Healthcare, patient, and work-related costs were measured. Health-related quality of life was assessed using EQ-5D-5 L at baseline, and after 3, 6, 9, and 12 months.
RESULTS: The add-on+TAU group showed slightly higher QALYs (0.674) than TAU-group (0.630) after 12 months. From a societal perspective, the intervention yielded an incremental cost-effectiveness ratio of €137,285 per QALY gained (95% CI: -€7,338 to €15,656; QALY gain: 0.0274). Healthcare costs were higher in the add-on+TAU group, primarily due to increased outpatient mental care costs (including intervention costs of €524.02/participant). The intervention showed a 35% probability of cost-effectiveness at an €80,000 willingness-to-pay threshold.
CONCLUSIONS: Although the add-on module reduced suicidal mental images, its cost-effectiveness remains uncertain. Modest QALY improvements did not justify increased healthcare and societal costs. Larger-scale studies with extended follow-up are needed.
CLINICAL TRIAL REGISTRATION: The trial was prospectively registered in the Netherlands Trial Registry (No. NTR7563).